UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Blood, 2016-10, Vol.128 (14), p.1821-1828

2016

Volltextzugriff (PDF)

The novel mechanism of lenalidomide activity

Blood, 2015-11, Vol.126 (21), p.2366-2369

2015

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide

Clinical pharmacokinetics, 2017-02, Vol.56 (2), p.139-152

2017

Volltextzugriff (PDF)

Peptidic degron for IMiD-induced degradation of heterologous proteins

Proceedings of the National Academy of Sciences - PNAS, 2019-02, Vol.116 (7), p.2539-2544

2019

Volltextzugriff (PDF)

Apremilast: A Review in Psoriasis and Psoriatic Arthritis

Drugs (New York, N.Y.), 2015-08, Vol.75 (12), p.1393-1403

Deeks, Emma D.

2015

Volltextzugriff (PDF)

Teratogenic effects of thalidomide: molecular mechanisms

Cellular and molecular life sciences : CMLS, 2011-05, Vol.68 (9), p.1569-1579

2011

Volltextzugriff (PDF)

Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies

European journal of pharmaceutical sciences, 2019-12, Vol.140, p.105068, Article 105068

2019

Volltextzugriff (PDF)

Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab

The Annals of pharmacotherapy, 2016-07, Vol.50 (7), p.555-568

2016

Volltextzugriff (PDF)

Development of Apremilast Solid Dispersion Using TPGS and PVPVA with Enhanced Solubility and Bioavailability

AAPS PharmSciTech, 2021-04, Vol.22 (4), p.142, Article 142

2021

Volltextzugriff (PDF)

Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions

Investigational new drugs, 2023-02, Vol.41 (1), p.60-69

2023

Volltextzugriff (PDF)

In Vivo Formation of Dihydroxylated and Glutathione Conjugate Metabolites Derived from Thalidomide and 5-Hydroxythalidomide in Humanized TK-NOG Mice

Chemical research in toxicology, 2012-02, Vol.25 (2), p.274-276

2012

Volltextzugriff (PDF)

Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment

Clinical cancer research, 2012-04, Vol.18 (8), p.2145-2163

2012

Volltextzugriff (PDF)

Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology

Chemical research in toxicology, 2016-12, Vol.29 (12), p.1903-1911

2016

Volltextzugriff (PDF)

Simulation of Human Plasma Concentrations of Thalidomide and Primary 5‑Hydroxylated Metabolites Explored with Pharmacokinetic Data in Humanized TK-NOG Mice

Chemical research in toxicology, 2015-11, Vol.28 (11), p.2088-2090

2015

Volltextzugriff (PDF)

Preparation, characterization, in vitro and in vivo anti-tumor effect of thalidomide nanoparticles on lung cancer

International journal of nanomedicine, 2018-01, Vol.13, p.2463-2476

2018

Volltextzugriff (PDF)

Development of an Extended-Release Formulation for Apremilast and a Level A in Vitro–in Vivo Correlation Study in Beagle Dogs

Chemical and Pharmaceutical Bulletin, 2016/11/01, Vol.64(11), pp.1607-1615

2016

Volltextzugriff (PDF)

Spotlight on pomalidomide: could less be more?

Leukemia, 2017-09, Vol.31 (9), p.1987-1989

2017

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report

Journal of clinical oncology, 2011-01, Vol.29 (3), p.316-323

2011

Volltextzugriff (PDF)

Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis

Expert opinion on pharmacotherapy, 2015-05, Vol.16 (7), p.1099-1108

2015

Volltextzugriff (PDF)

Lenalidomide for the treatment of B-cell lymphoma

Expert opinion on investigational drugs, 2016-09, Vol.25 (9), p.1103-1116

2016

Volltextzugriff (PDF)

Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity

Bioorganic & medicinal chemistry letters, 2013-01, Vol.23 (1), p.360-365

2013

Volltextzugriff (PDF)

Pomalidomide: First Global Approval

Drugs (New York, N.Y.), 2013-05, Vol.73 (6), p.595-604

2013

Volltextzugriff (PDF)

Population pharmacokinetics of lenalidomide in multiple myeloma patients

Cancer chemotherapy and pharmacology, 2017-01, Vol.79 (1), p.189-200

2017

Volltextzugriff (PDF)

Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue

Journal of pharmaceutical and biomedical analysis, 2014-01, Vol.88, p.262-268

2014

Volltextzugriff (PDF)

Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA

The Journal of Toxicological Sciences, 2018, Vol.43(6), pp.369-375

2018

Volltextzugriff (PDF)

1 – 25 von 163

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(147)
Mit Volltextzugriff
(129)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(137)
Life Sciences & Biomedicine
(132)
Humans
(117)
Thalidomide - Pharmacokinetics
(102)
Thalidomide - Analogs & Derivatives
(73)
Pharmacology & Pharmacy
(68)
Animals
(66)
Thalidomide
(61)
Pharmacokinetics
(51)
Thalidomide - Therapeutic Use
(51)
Biological And Medical Sciences
(44)
Medical Sciences
(44)
Thalidomide - Pharmacology
(43)
Multiple Myeloma - Drug Therapy
(39)
Pharmacology. Drug Treatments
(38)
Thalidomide - Adverse Effects
(38)
Multiple Myeloma
(36)
Thalidomide - Administration & Dosage
(33)
Oncology
(32)
Female
(27)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

The novel mechanism of lenalidomide activity

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide

Peptidic degron for IMiD-induced degradation of heterologous proteins

Apremilast: A Review in Psoriasis and Psoriatic Arthritis

Teratogenic effects of thalidomide: molecular mechanisms

Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies

Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab

Development of Apremilast Solid Dispersion Using TPGS and PVPVA with Enhanced Solubility and Bioavailability

Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions

In Vivo Formation of Dihydroxylated and Glutathione Conjugate Metabolites Derived from Thalidomide and 5-Hydroxythalidomide in Humanized TK-NOG Mice

Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment

Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology

Simulation of Human Plasma Concentrations of Thalidomide and Primary 5‑Hydroxylated Metabolites Explored with Pharmacokinetic Data in Humanized TK-NOG Mice

Preparation, characterization, in vitro and in vivo anti-tumor effect of thalidomide nanoparticles on lung cancer

Development of an Extended-Release Formulation for Apremilast and a Level A in Vitro–in Vivo Correlation Study in Beagle Dogs

Spotlight on pomalidomide: could less be more?

Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report

Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis

Lenalidomide for the treatment of B-cell lymphoma

Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity

Pomalidomide: First Global Approval

Population pharmacokinetics of lenalidomide in multiple myeloma patients

Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue

Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA

Aktive Filter

Suchergebnisse filtern